Serum peptide profiling: Identifying novel cancer biomarkers for early disease detection

Acta Biomedica

Volumn 78, Issue SUPPL. 1, 2007, Pages 123-128

  Martorella, Andrew ^a   Robbins, Richard ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Biomarkers; Biosignature profile; Human proteome; MALDI TOF; Mass spectrometry; Peack alignment; Peptide profiling; Proteomics; Sample processing

Indexed keywords

MICROSPHERE; PEPTIDE; TUMOR MARKER;

ALGORITHM; ARTICLE; AUTOMATION; BLOOD; COHORT ANALYSIS; COMPUTER PROGRAM; EARLY DIAGNOSIS; FEMALE; HUMAN; IMMUNOMAGNETIC SEPARATION; INSTRUMENTATION; ISOLATION AND PURIFICATION; MALE; MASS SPECTROMETRY; METASTASIS; METHODOLOGY; MOLECULAR WEIGHT; PATHOLOGY; PREDICTION AND FORECASTING; PROTEOMICS; ROBOTICS; SENSITIVITY AND SPECIFICITY; THYROID TUMOR;

ALGORITHMS; AUTOMATION; COHORT STUDIES; EARLY DIAGNOSIS; FEMALE; HUMANS; IMMUNOMAGNETIC SEPARATION; MALE; MICROSPHERES; MOLECULAR WEIGHT; NEOPLASM METASTASIS; PEPTIDES; PREDICTIVE VALUE OF TESTS; PROTEOMICS; ROBOTICS; SENSITIVITY AND SPECIFICITY; SOFTWARE; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 34347220514     PISSN: 03924203     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Simpson RJ. Proteins and proteomics: a laboratory manual. Cold Spring Harbor, Cold Spring Harbor Laboratory Press, 2002: chapter 1.
2. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359: 572-7.
3. Petricoin EF, Ornstein DK, Paweletz CP, et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 2002; 94: 1576-8.
4. Adam BL, Qu Y, Davis JW, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002; 62: 3609-14.
5. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002; 48: 1296-304.
6. Robbins R, Drucker W, Hann L, Tuttle RM. Advances in the detection of residual thyroid carcinoma. Adv Intern Med 2001; 46: 277-294.
7. Wang W, Macapinlac H, Larson SM, et al. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 1999; 84: 2291-2302.
8. Wang W, Larson SM, Fazzari M, et al. Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 2002; 85: 1107-13.
9. Mazzaferri EL, Robbins RJ, Spencer CA, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003; 88: 1433-41.
10. Robbins RJ, Tuttle RM, Sharaf RN, et al. Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. J Clin Endocrinol Metab 2001; 86: 619-625.
11. Robbins RJ, Chon JT, Fleisher M, et al. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? J Clin Endocrinol Metab 2002; 87: 3242-324.
12. Aebersold R, Mann M. Mass Spectrometry-Based Proteomics. Nature 2003; 422: 198-207.
13. Petricoin E, Liotta L. Mass Spectrometry-based Diagnostics: The Upcoming Revolution in Disease Detection. Clin Chem 2003; 49: 533-4.
14. Tirumalai R, Chan K, Prieto D, Issaq H, Conrads T, Veenstra T. Characterization of the Low Molecular Weight Human Serum Proteome. Mol Cell Proteomics 2004; 3: 311-26.
15. Conrads T, Fusaro V, Ross S, et al. High-resolution serum proteomic features for ovarian cancer detection. Endocrine-Related Cancer 2004; 11: 163-78.
16. Villanueva J, Philip J, Entenberg D, et al. Serum Peptide Profiling by Magnetic Particle-Assisted, Automated Sample Processing and MALDI-TOF Mass Spectrometry. Anal Chem 2004; 76: 1560-70.
17. Villanueva J, Philip J, Chaparro C, et al. Correcting Common Errors in Identifying Cancer-Specific Serum Peptide Signatures. J Proteome Res 2005; 4: 1060-72.